×
About 380 results

ALLMedicine™ Nail Disorders Center

Research & Reviews  102 results

Treatment of several nail disorders reviewed
https://www.mdedge.com/dermatology/article/261287/hair-nails/treatment-several-nail-disorders-reviewed
Thomas R. Collins

Feb 17th, 2023 - ORLANDO – From differentiating them from mimics to choosing the best treatment course, Molly Hinshaw, MD, reviewed some of the ins and outs of managing nail disorders at the ODAC Dermatology, Aesthetic, & Surgical Conference. Dr.

Q-switched Nd:YAG laser versus itraconazole pulse therapy in treatment of onychomycosis...
https://doi.org/10.1111/jocd.15660
Journal of Cosmetic Dermatology; Nasif GA, Amin AA et. al.

Jan 31st, 2023 - Onychomycosis (OM) represents about 50% of nail disorders. Oral antifungals have proven efficacy in the treatment of onychomycosis but their associated side effects limit their use. Accordingly, there is an increased need for a safe and effective ...

Analysis of Impact of KeryFlex on Quality of Life for Retronychia or Lichen Planus Adult Patients
https://clinicaltrials.gov/ct2/show/NCT05699499

Jan 26th, 2023 - Retronychia is the growth of the proximal nail plate into the proximal nail fold which was first described in 1999 by De Berker and Rendall. The disorder is common and most frequently affects women (~82%); the estimated average age is 39 years. Th...

The effect of COVID-19 on development of hair and nail disorders: a Turkish multicenter...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874876
International Journal of Dermatology; Kutlu Ö, Demircan YT et. al.

Oct 26th, 2022 - A broad spectrum of skin diseases, including hair and nails, can be directly or indirectly triggered by COVID-19. It is aimed to examine the type and frequency of hair and nail disorders after COVID-19 infection. This is a multicenter study conduc...

Nail Salon Safety: From Nail Dystrophy to Acrylate Contact Allergies.
https://doi.org/10.12788/cutis.0592
Cutis Nanda S

Oct 1st, 2022 - Nail cosmetics are an integral practice in many patients' lives. However, the manicuring process can result in nail damage via instrumentation, allergens in nail polish, and infections. Many of these nail disorders are preventable through proper e...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  6 results

Analysis of Impact of KeryFlex on Quality of Life for Retronychia or Lichen Planus Adult Patients
https://clinicaltrials.gov/ct2/show/NCT05699499

Jan 26th, 2023 - Retronychia is the growth of the proximal nail plate into the proximal nail fold which was first described in 1999 by De Berker and Rendall. The disorder is common and most frequently affects women (~82%); the estimated average age is 39 years. Th...

Foot Self-care in Older Adults
https://clinicaltrials.gov/ct2/show/NCT03656341

Oct 25th, 2019 - One in three older adults have foot problems such as bunions, corns, calluses, foot pain, or nail disorders, but those problems are often ignored or overlooked until they threaten mobility or quality of life. With proper self-management, skin and ...

Subclinical Nail Involvement in Relevant Skin Diseases
https://clinicaltrials.gov/ct2/show/NCT04092413

Sep 17th, 2019 - Nails are characteristically affected in skin diseases such as psoriasis (speckling, psoriatic oil spot, crumbling nails, pachyonychia) ,lichen( anonychia, dystrophy) ,alopecia areata (speckling, trachyonychia, longitudinal grooves, leukonychia), ...

Prevalence of Obstructive Sleep Apnea (OSA) in Patients With Lymphedema, Admitted for Intensive Decongestive Physiotherapy
https://clinicaltrials.gov/ct2/show/NCT02979184

Apr 18th, 2018 - Lymphedema is the result of an intra-tissue fluid accumulation by failure of the lymphatic system to absorb the excess fluid from the veinulo-capillary circulation. Lymphedema can be primitive with aplasia or hypoplasia of the lymphatic vessels or...

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.
https://clinicaltrials.gov/ct2/show/NCT00356915

Feb 9th, 2017 - Onychomycosis is common and accounts for about half of all nail disorders. Usually the cause is due to dermatophytes, either Trichophyton rubrum (71%) or Trichophyton mentagrophytes (20%) but may also be due to yeast infection, usually Candida alb...

see more →

News  35 results

Treatment of several nail disorders reviewed
https://www.mdedge.com/dermatology/article/261287/hair-nails/treatment-several-nail-disorders-reviewed
Thomas R. Collins

Feb 17th, 2023 - ORLANDO – From differentiating them from mimics to choosing the best treatment course, Molly Hinshaw, MD, reviewed some of the ins and outs of managing nail disorders at the ODAC Dermatology, Aesthetic, & Surgical Conference. Dr.

Talquetamab Plus Daratumumab Generates High Response Rate in CD38-Refractory Myeloma
https://www.onclive.com/view/talquetamab-plus-daratumumab-generates-high-response-rate-in-cd38-refractory-myeloma

Sep 29th, 2022 - The combination of talquetamab and daratumumab and hyaluronidase-fihj (Darzalex Faspro) led to early onset and durable responses that deepened over time in patients with heavily pretreated multiple myeloma, most of whom were anti-CD38 refractory, ...

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions
https://www.onclive.com/view/talquetamab-adverse-event-management-in-myeloma-requires-early-oral-dermatologic-interventions

Aug 25th, 2022 - Effective methods of mitigating oral and dermatologic treatment-emergent adverse events (TEAEs) commonly reported with talquetamab may include preventative tactics initiated at the start of therapy. In a presentation during the 19th International ...

Spotted white fingernails
https://www.mdedge.com/familymedicine/article/257109/dermatology/spotted-white-fingernails
MDedge Family Medicine;

Aug 18th, 2022 - White nail changes are broadly called leukonychia: “leuko” meaning white and “nychia” referring to the nail. Scattered or single asymptomatic cloudy white nail lesions occurring without other associated skin or nail disorders are more specifically.

Talquetamab Continues to Impress in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/talquetamab-continues-to-impress-in-relapsed-refractory-multiple-myeloma

Sep 10th, 2021 - Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose (RP2D) of 405 ...

see more →